In a study exploring the efficacy of anti-sense oligonucleotide (ASO) therapy for the treatment of epilepsy, a reduction in Scn8a brain expression levels by ASO was found to extend the lifespan and delay SUDEP onset in Kcna1 KO mice; however, seizure burden was not significantly improved [98]. The gene discussed is SCN8A; the disease is epilepsy.